Drugs / Gossypol Acetate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00390403 | Feb 2007 → Jun 2009 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07656766 | Jul 2026 → Sep 2027 expected | colorectal cancer | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07337551 | Feb 2026 → Feb 2028 expected | — | Guiying Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06133088 | Aug 2023 → Dec 2024 | Her2-receptor negative breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01977209 | Sep 2013 → Feb 2016 | non-small cell lung carcinoma | Third Military Medical University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gossypol acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07337551 ↗ |
| Known as | AT-101 | “Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme” NCT00390403 ↗ |
| Known as | Gossypol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01977209 ↗ |
| Action | Inhibit | “gossypol was the natural inhibitor of apyrimidinic endonuclease 1 (APE1)” NCT01977209 ↗ |
| Route | Oral | “Patients receive oral gossypol” NCT00390403 ↗ |
| Target | APE1 | “gossypol was the natural inhibitor of apyrimidinic endonuclease 1 (APE1)” NCT01977209 ↗ |